BioSpace News Archive

A leading researcher at Université de Montréal will leverage IRICoR’s expertise in accelerating drug discovery projects and Valence’s AI-enabled platform to design highly selective drug candidates against a newly identified target.

“This new patent further strengthens our intellectual property focused on the treatment of neurodegenerative diseases,” commented Maria Maccecchini, Ph.D., CEO of Annovis.

empowerDX, a Eurofins (Paris:ERF) subsidiary, announced the launch of its direct-to-consumer, FDA-emergency use authorised, COVID-19 Home Collection Kit on Amazon

Transgene: Significant Milestones Achieved on All Drug Candidates in 2020 and Financial Visibility until 2022 TG4050 : first patients treated in two clinical trials of the novel individualized immunotherapy based on the myvac ® technology – First data expected in 4Q 2021 TG4001 : expanded randomized Phase II trial to start in HPV-positive anogenital cancers, based on encouraging Phase Ib/II data

Uromedica, Inc. announces the initiation of its FDA Investigational Device Exemption trial for ACT® to evaluate its safety and efficacy for treatment of female SUI.

Perflow Medical, a private, Israeli-based innovator of solutions for neurovascular treatment, today announced it has launched to the European market the Cascade™ 17 Non-Occlusive Remodeling Net.

Chimeron Bio, an RNA company pioneering a novel class of mRNA-based vaccines and therapeutics, is pleased to announce the appointment of Dr. Juan José Daboub and Dr. Wilmot James to its Accessible Medicines Advisory Board.

uLab Systems™, the creator of the uSmile™ Clear Aligner System, announced today that it has entered into a supply agreement with the SG Management LLC (Schulman Group), a pre-eminent Orthodontic Service Organization consisting of the top 2% of orthodontic practices in the United States.

The hepatitis C virus (HCV) therapeutics market in Japan is highly competitive with stiff competition between Gilead and AbbVie. However, AbbVie has taken an edge over Gilead in terms of HCV-related digital initiatives, finds GlobalData, a leading data and analytics company.

Company reported ZILRETTA® (triamcinolone acetonide extended-release injectable suspension) net sales of $85.6 million for full-year 2020 representing 17% growth over 2019